更新于：2024-12-17
Calcium Gluconate
葡萄糖酸钙
更新于：2024-12-17
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1971-11-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构
分子式C12H24CaO14 |
InChIKeyAEKBAPDBAHVOEH-IYEMJOQQSA-N |
CAS号299-28-5 |
关联
35
项与 葡萄糖酸钙 相关的临床试验Empiric Calcium Versus Lab Based Treatment in Massive Transfusion Trauma Patients: A Feasibility Randomized Controlled Trial
Effect of prophylactic intravenous calcium gluconate compared to placebo on postpartum blood loss in women with hypertensive disorders of pregnancy at term gestation undergoing emergency caesarean delivery: A randomised, double-blinded, placebo-controlled. - nill
CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial
100 项与 葡萄糖酸钙 相关的临床结果
登录后查看更多信息
100 项与 葡萄糖酸钙 相关的转化医学
登录后查看更多信息
100 项与 葡萄糖酸钙 相关的专利（医药）
登录后查看更多信息
2,407
项与 葡萄糖酸钙 相关的文献（医药）2025-02-01FOOD CHEMISTRY
Formation of furan and furan derivatives in baby food products
Article
作者: Oellig, Claudia ; Schöpf, Alena ; Steliopoulos, Panagiotis
A comprehensive analysis of 89 commercial baby food samples showed the highest levels of furan in ready-to-eat full meals and vegetable purees (12-118 μg/kg). The alkylated furans (2- and 3-methylfuran, 2-ethylfuran, 2-pentylfuran) were predominantly found in these baby food categories. Furfuryl alcohol was notably abundant in ready-to-eat cereal porridge (3,550-13,100 μg/kg). The addition of lactose to self-made cereal porridge strongly influenced the formation of furfuryl alcohol. After reheating selected commercial baby food samples, a reduction of furan by 38 %, methylfurans by 28 %, and 2-ethylfuran by 26 % has been achieved. Raw materials, vegetable varieties, and storage conditions had a major impact on furan formation, which requires an adaptation of processing parameters. The most promising mitigation of furan (by 44 %) and most furan derivatives in vegetable puree were achieved by adding the additive calcium lactate gluconate. In contrast, in cereal porridge, the formation of furfuryl alcohol was reduced by 28 %.
2025-02-01TRANSFUSION AND APHERESIS SCIENCE
Comparison of different concentrations of calcium gluconate added in replacement fluid to maintain ionised calcium levels during therapeutic plasma exchange procedures
Article
作者: Prinja, Nippun ; Sahni, Aarushi ; Paul, Preeti ; Hans, Rekha ; Mahesh, Karthik Vinay ; Takkar, Aastha ; Sharma, Ratti Ram ; Lamba, Divjot Singh ; Kumari, Sangeeta
INTRODUCTION:
Therapeutic plasma exchange (TPE) is generally well tolerated but Anticoagulant Citrate Dextrose Solution A (ACD-A) can cause citrate mediated hypocalcaemia so, adding calcium gluconate to the replacement fluid is effective in preventing this complication. We aimed to compare the effect of different concentrations of 10 % calcium gluconate (9.3 mg of elemental calcium/100 ml Vs 18.6 mg of elemental calcium/100 ml) added to 5 % Human Serum Albumin (HSA) on intraprocedural and post procedural ionised calcium (iCa2+) levels in patients with neurological conditions undergoing TPE.
MATERIAL AND METHODS:
This study comprised of 100 TPE procedures divided into two groups of 50 each. In group 1, 5 ml of 10 % calcium gluconate was added in 500 ml of 5 % HSA (9.3 mg of elemental calcium/100 ml) and in group 2, 10 ml of 10 % calcium gluconate was added (18.6 mg of elemental calcium/100 ml) in 5 % of HSA. Ionised calcium was noted-pre, intra and post-procedure and compared within the groups along with other procedural parameters and adverse events if any.
RESULTS:
We observed that mean intraprocedural ionised calcium levels were comparable (p = 0.579) in both the groups, but post-procedural iCa2+ levels significantly decreased (p = 0.003) in group-1 as compared to group-2. Symptomatic hypocalcaemia was seen in 14 % of patients group 1 compared to 2 % in group-2. Vasovagal reactions were 8 % in group-1 % and 2 % in group-2.
CONCLUSION:
Prophylactic addition of 18.6 mg of elemental calcium/100 ml of 5 % HSA is safe to maintain levels of iCa2+ throughout the procedure with lower chances of adverse events related to hypocalcaemia.
2025-02-01Journal of the Mechanical Behavior of Biomedical Materials
Calcium sulfate-based load-bearing bone grafts with patient-specific geometry
Article
作者: Mirmohammadi, Seyed Alireza ; Pasini, Damiano ; Barthelat, Francois
The treatment of bone defects with complex three-dimensional geometry presents challenges in terms of bone grafting and restoration. In this paper, we propose a rapid and effective method that uses 3D printing, ceramic casting, and the incorporation of mesh reinforcement to create load-bearing bone grafts with patient-specific three-dimensional geometry. Using two types of facial bones as examples, we show that this fabrication method has a high degree of geometrical fidelity. We also experimentally study the fracture behavior of six different architectures designed for the treatment of mandibular defects, one of the principal load-bearing facial bones. These design configurations include un-reinforced calcium sulfate samples, and samples reinforced with one or two layers of stainless steel, poly (lactic acid), and poly (L-lactic acid). The results suggested a trade-off between energy dissipation and maximum load based on the position of the metal mesh in the sample. Samples reinforced with one layer of metallic mesh at their lowermost margin exhibited a 17% higher stiffness and a 21.3% higher peak load, while samples with a layer of metal mesh embedded within dissipated 16% more energy. Samples with two layers of metallic mesh demonstrated the highest improvements among all samples, dissipating 5767.85% more energy and exhibiting a peak load 145.6% higher compared to plain CS. The improvements in stiffness for SD, SL, and S2 were 3%, 21.3%, and 21.9% respectively compared to the plain ceramic. In contrast, PLA mesh improved energy dissipation by 96.71% but reduced the peak load by 29.18%, while PLLA mesh decreased both the peak load and the dissipated energy by 13.05% and 35.31%, respectively. While PLA mesh reduced stiffness by 11% compared to plain CS, PLLA mesh-reinforced samples were slightly stiffer than pure CS by 1.6%.
100 项与 葡萄糖酸钙 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 低钙血症 | 日本 | 1971-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | Prophylactic infusion of calcium gluconate | 糧遞簾簾餘夢範觸齋憲(窪淵壓衊繭餘淵積艱餘) = 遞鏇觸壓廠鏇襯壓獵憲 壓壓積齋鏇簾鬱鹽鏇網 (鬱鏇顧衊壓廠積網鑰製 ) | 不佳 | 2024-08-01 | ||
Placebo | 蓋築網齋觸窪網願鏇選(構醖鹹構願艱獵鹹糧遞) = 獵憲襯廠願簾繭醖構壓 簾鬱窪憲簾鹽築醖窪鬱 (淵蓋齋選鑰製膚糧壓夢 ) 更多 | ||||||
N/A | - | Calcium 5 group | 衊襯醖範範廠顧醖築醖(鹹夢膚壓夢壓簾夢衊鑰) = 鑰鏇糧餘鑰構憲簾顧憲 廠網醖遞襯壓鹽窪範餘 (壓齋憲蓋網遞壓築淵蓋 ) | - | 2021-03-29 | ||
Calcium 10 group | 衊襯醖範範廠顧醖築醖(鹹夢膚壓夢壓簾夢衊鑰) = 醖獵衊願襯齋壓構膚齋 廠網醖遞襯壓鹽窪範餘 (壓齋憲蓋網遞壓築淵蓋 ) | ||||||
临床3期 | 53 | Zoledronate+Calcium+Cholecalciferol (Treatment With Zoledronate, Calcium and Cholecalciferol) | 夢選製憲積鏇蓋襯鬱範(襯遞艱積壓獵餘壓壓蓋) = 鹹襯範夢鏇簾膚構壓構 繭鹽襯襯壓憲選蓋鏇蓋 (鬱鬱範觸選網窪鑰範廠, 鑰淵積遞觸觸襯網艱鏇 ~ 糧醖構艱糧憲鑰壓鏇餘) 更多 | - | 2020-11-19 | ||
Calcium+Cholecalciferol (Treatment With Calcium and Cholecalciferol) | 夢選製憲積鏇蓋襯鬱範(襯遞艱積壓獵餘壓壓蓋) = 選鬱鑰繭鏇鏇遞衊窪夢 繭鹽襯襯壓憲選蓋鏇蓋 (鬱鬱範觸選網窪鑰範廠, 獵壓鬱蓋夢鹹夢艱艱繭 ~ 夢鬱積襯襯襯製蓋淵衊) 更多 | ||||||
临床3期 | 50 | Conventional treatment (morphine 0.1 mg/kg + normal saline) | 築蓋艱衊觸壓繭醖鏇艱(願艱壓夢獵網廠醖鹹網) = 鑰遞範築選鬱製鏇醖艱 餘夢淵鬱淵鏇夢膚鬱選 (糧艱淵壓積壓構繭網膚 ) | - | 2020-03-17 | ||
Conventional treatment plus 1 g of intravenous calcium gluconate | 築蓋艱衊觸壓繭醖鏇艱(願艱壓夢獵網廠醖鹹網) = 餘遞繭顧壓選淵齋構繭 餘夢淵鬱淵鏇夢膚鬱選 (糧艱淵壓積壓構繭網膚 ) | ||||||
临床3期 | 362 | 襯衊淵顧範廠獵襯構壓(觸淵鏇餘範淵壓鏇餘鹹) = 選膚鹹廠齋範鬱鬱糧醖 範夢製衊醖襯淵艱觸衊 (齋淵蓋積鹽夢鏇蓋築遞, 齋繭鬱齋壓壓淵獵鏇獵 ~ 襯廠鬱觸糧艱簾糧觸淵) 更多 | - | 2019-05-23 | |||
placebo+Oxaliplatin (Arm II) | 襯衊淵顧範廠獵襯構壓(觸淵鏇餘範淵壓鏇餘鹹) = 網鬱蓋製選壓願淵獵夢 範夢製衊醖襯淵艱觸衊 (齋淵蓋積鹽夢鏇蓋築遞, 觸選顧製繭選憲鏇廠夢 ~ 襯鑰衊範範膚鑰蓋簾積) 更多 | ||||||
临床3期 | 104 | 願繭範網鹽獵鑰範淵鹹(鹽鬱醖夢築願淵壓繭膚) = 襯壓網鏇鹹鏇簾選繭繭 衊壓艱鹽壓膚簾醖鏇淵 (鑰憲廠醖齋顧積觸繭觸, 獵觸築範壓選膚製夢鏇 ~ 鬱淵選選獵鑰廠簾繭鹽) 更多 | - | 2013-03-25 | |||
placebo (Placebo) | 願繭範網鹽獵鑰範淵鹹(鹽鬱醖夢築願淵壓繭膚) = 獵繭膚鏇鏇願窪獵廠範 衊壓艱鹽壓膚簾醖鏇淵 (鑰憲廠醖齋顧積觸繭觸, 築膚範鏇範夢築獵鏇積 ~ 廠築鹹築觸淵鏇築積鏇) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用